Overview of Katadolon PR

Property	Description
Active Ingredient	Flupirtine maleate
Form	Prolonged Release (PR) tablet
Pharmacological Class	Centrally acting nonopioid analgesic, SNEPCO
Common Use	Relief from pain conditions
Origin	Synthetic

Katadolon PR is a synthetic medicinal product containing the active substance Flupirtine maleate, which is classified as a centrally acting nonopioid analgesic. It is a derivative of aminopyridine and operates by modulating the central nervous system to relieve pain. As a prescription-only medication, this specific formulation is primarily distributed in European markets.

What Type of Medicine is Katadolon PR?

Katadolon PR belongs to a unique pharmacological class identified as a Selective Neuronal Potassium Channel Opener (SNEPCO). This mechanism is distinct from standard analgesics: while non-steroidal anti-inflammatory drugs (NSAIDs) typically inhibit enzyme activity, Flupirtine works by activating specific potassium channels (Kv7) on nerve cells. This action stabilizes the neuronal membrane and reduces the excessive electrical activity that often underlies pain states. Flupirtine is classified as a central analgesic, a classification that reflects the drug's role in alleviating discomfort through central action.

Understanding the Prolonged Release (PR) Formulation

The designation PR in Katadolon PR signifies a Prolonged Release tablet, an oral dosage form engineered for controlled delivery of Flupirtine maleate. This formulation uses specialized pharmaceutical excipients within the tablet matrix to ensure the active ingredient is released slowly and continuously over an extended duration. This contrasts with immediate-release forms where the full dose is released rapidly. The benefit of this controlled delivery system is the potential for sustained analgesic relief, aiming to maintain consistent pain relief, particularly in scenarios such as chronic musculoskeletal discomfort.

What is the General Therapeutic Purpose of Flupirtine?

The general therapeutic purpose of this medication is to provide effective, sustained relief for various pain conditions by acting as a central modulator of pain transmission. Because of its dual mechanism—calming overactive nerve signals and also exhibiting supplementary skeletal muscle relaxant properties—it offers a combined therapeutic benefit for patient discomfort. Flupirtine has historically been used as an alternative analgesic when other painkillers, such as NSAIDs, were not suitable, making it a recognized option in pain management protocols.

What side effects are possible with Katadolon PR?

Official Safety Profile and Adverse Reactions

The safety profile of Katadolon PR (Flupirtine maleate) is characterized by adverse reactions that are classified according to incidence rates documented in official regulatory sources, primarily focusing on hepatobiliary and central nervous system effects.

Frequency-Classified Adverse Reactions

Classification	Examples of Reported Adverse Reactions
Very Common (ge 1/10)	Fatigue (often pronounced at the start of treatment).
Common (ge 1/100 to < 1/10)	Dizziness, sleep disorders, headache, nervousness, nausea, vomiting, constipation, dry mouth, and increased liver enzyme values (transaminases).
Uncommon (ge 1/1,000 to < 1/100)	Confusion, visual disturbances, rash, and allergic reactions (e.g., urticaria).

Serious Adverse Reactions and Safety Constraints

The most critical safety consideration documented in regulatory assessments is the potential for serious hepatotoxicity. Rare cases of hepatitis and acute liver failure have been reported. This risk is specifically linked to treatment duration and cumulative exposure.

Due to this profile, the medicine is subject to strict regulatory constraints and is contraindicated in individuals with pre-existing liver disease, severe hepatic impairment, or a history of alcohol abuse. It is also restricted for use in patients with myasthenia gravis or a risk of hepatic encephalopathy.

Furthermore, official regulatory notes stipulate that the use of Flupirtine maleate is generally limited to a maximum treatment period (e.g., two weeks) to mitigate the risk of serious liver injury. The potential for CNS effects, such as dizziness and confusion, may be increased in older adults.

Overdose and Emergency Response

Overdose and when to seek help

This information is based strictly on regulatory descriptions of overdose manifestations and required emergency actions for Katadolon PR (Flupirtine maleate).

Documented Overdose Manifestations and Severe Outcomes

Overdose or toxicity with Katadolon PR may present with Central Nervous System (CNS) effects such as drowsiness, dizziness, and confusion, alongside gastrointestinal disturbances like nausea and vomiting. The most serious and life-threatening outcome documented by regulatory authorities is Acute Liver Failure (ALF) and severe Hepatotoxicity. This can lead to the need for liver transplantation in reported severe cases.

Regulator-Mandated Emergency Actions

Action Required	Condition Triggering Action
Discontinue treatment immediately	Clinical symptoms or abnormal liver function tests consistent with liver disease.
Seek medical advice immediately	Appearance of clinical signs compatible with hepatic damage, such as jaundice, dark urine, or severe fatigue.
Urgent hospital management	Any suspected overdose or presence of life-threatening symptoms.

Official Management and Considerations

Management of an overdose is primarily symptomatic and supportive, as regulatory documents do not specify a known antidote. Close surveillance and hospital monitoring are required for severe cases. Patients with pre-existing hepatic impairment or a history of alcohol abuse are noted to have an increased risk for severe toxicity outcomes that would be amplified by overdose.

Therapeutic Uses of Katadolon PR

What Katadolon PR Treats: Main Uses and Benefits

Katadolon PR (Flupirtine maleate prolonged release) is commonly used to help with symptomatic relief that is sustained for conditions presenting with mild to moderate pain. Its therapeutic use is generally applied in situations involving acute pain, and is relevant when supportive symptom management is appropriate, particularly as an option distinct from certain other analgesics. The use of flupirtine-containing medicines is guided by strict clinical criteria. The prolonged-release (PR) formulation is relevant for easing symptoms that require sustained symptomatic support.

The medication primarily helps address symptoms related to musculoskeletal discomfort with associated muscle tension and acute, post-event nociceptive discomfort. It is applicable in conditions such as low back pain, tension headaches, pain following trauma, and discomfort after surgical procedures.

“The medication helps ease the overall burden of symptoms that are linked to organ-specific functional stress and discomfort.”

Musculoskeletal Pain with Associated Muscle Tension

This domain covers symptomatic discomfort arising from the muscles and skeletal structure, such as low back pain and tension headaches, where symptoms of increased neurological or muscular activity contribute to the pain. The medication is relevant in clinical settings marked by heightened physiological tension, offering dual support that helps ease the overall burden of symptoms while simultaneously contributing to easing symptoms of increased muscular activity and tension. This supports general well-being and assists with maintaining functional stability.

Quick Fact: Relevant for Symptoms of Increased Muscular Activity Katadolon PR is generally considered relevant when symptoms related to physical discomfort are compounded by symptoms of increased neurological or muscular activity, supporting general well-being during symptomatic phases.

Acute and Post-Event Nociceptive Discomfort

Katadolon PR is applied in contexts where additional support for symptom management is needed for acute pain due to tissue damage (nociceptive pain). This includes pain following trauma or surgical procedures (e.g., orthopedic or dental). As a prolonged-release form, it may assist in maintaining symptomatic stability for persistent discomfort over extended periods, making it relevant in contexts involving acute or unstable symptom patterns where short-term, sustained assistance helps patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Katadolon PR?

Official regulatory bodies have imposed strict eligibility criteria for Katadolon PR (flupirtine maleate), limiting its use to a narrow patient population due to safety concerns.

Eligibility Status	Restriction/Condition (Adults Only)
Allowed (Restricted)	Used for acute (short-term) pain only.
Second-Line Use	Only if other standard painkillers (like NSAIDs or weak opioids) are contraindicated for the patient.
Duration Limit	Treatment must not exceed 14 days (two weeks).

Absolute Contraindications

The medicine must not be used by certain populations. Absolute non-eligibility is defined by a high risk of liver toxicity, and includes patients with any pre-existing liver disease or those with alcohol abuse problems. It is also contraindicated for patients concurrently taking other medicines known to cause liver damage.

Special Population Rules

Use in children and adolescents (under 18) is not established and is not recommended. For older adults or patients with renal impairment, dose reduction is typically necessary. Use during pregnancy or breastfeeding is not recommended; nursing mothers must cease breastfeeding if treatment is prescribed.

What should I know about interactions with other medicines?

Katadolon PR Interactions with other medicines and products

The official regulatory profile for Katadolon PR (Flupirtine maleate) defines interactions structured around the risks of additive toxicity, central nervous system potentiation, and altered exposure of co-administered medicines.

Contraindicated Combinations and Substance Restrictions

Use is formally prohibited with medicinal products known to cause Drug-Induced Liver Injury (DILI). The product is also contraindicated in patients with chronic alcoholism or pre-existing liver disease. Alcohol consumption must be strictly avoided due to the potentiation of central sedative effects and the aggravation of liver toxicity risk.

Pharmacodynamic and Exposure Interactions

Co-administration with other sedatives, including Benzodiazepines, results in additive CNS effects such as increased tiredness and dizziness. An interaction with Oral Anticoagulants, specifically Warfarin, may increase the anticoagulant effect, requiring mandatory monitoring of Prothrombin Time (PT). The co-administration of Paracetamol (Acetaminophen) increases the hepatotoxic potential, necessitating the monitoring of hepatic transaminase levels. Furthermore, Flupirtine maleate may displace other highly protein-bound medicines, potentially increasing their free concentration.

Population-Specific Interaction Notes

The clearance of Katadolon PR is altered in patients with hepatic impairment, renal impairment, and in elderly patients (over 65 years). This alteration results in a prolonged elimination half-life, which requires an interaction-related adjustment to maintain appropriate exposure levels.

Mechanism of Action

The active ingredient operates primarily as a Selective Neuronal Potassium Channel Opener (mathbfSNEPCO), directly engaging voltage-gated mathbfKv7 channels on nerve cells. By activating these channels, the drug promotes the outflow of potassium ions (mathbfK^+) . This mechanism rapidly hyperpolarizes the nerve cell membrane, which stabilizes its electrical potential and reduces the repetitive firing of action potentials in hyperexcitable central pathways.

The resulting stabilization of the nerve membrane initiates a cascade that indirectly modulates the function of mathbfNMDA receptors by enhancing the natural magnesium mathbf( Mg^2+) block of the channel. This limits the influx of excessive calcium ions (mathbfCa^2+) into the cell. Furthermore, the central action extends to the motor system, causing inhibition of polysynaptic reflexes in the spinal cord. These combined effects result in the physiological consequences of modulation of nerve signal propagation and decreased spinal polysynaptic reflex activity.

Dosage and Administration Information

Katadolon PR is formulated for oral administration using a Prolonged-Release (PR) tablet that typically contains 400 mg of Flupirtine maleate. The integrity of this specialized formulation is maintained by swallowing the tablet whole, ensuring it is not crushed or chewed. This administration method supports the intended once-daily dosing pattern.

The standard adult regimen involves taking the 400 mg PR tablet once daily. The total amount of Flupirtine maleate administered daily must not exceed 600 mg. A critical constraint on this usage is the mandatory limit on the duration of treatment, which must not exceed 14 days (two weeks), defining its application as a short-term course only.

Specific procedural adjustments to the standard regimen are required for certain populations to ensure proper use. For older adults and patients with established renal or hepatic impairment, the dosage must be systematically reduced by 50%. This medication is not recommended for use in children and adolescents under the age of 18 years. These specified dose reductions and duration limits define the strict protocol for the administration of Katadolon PR.

Recent Clinical Evidence

Research evidence / Overview of studies for Katadolon PR

Evidence for Use in Musculoskeletal Pain

Research examined this medication primarily in adult populations experiencing sub-acute or chronic musculoskeletal discomfort, particularly those with low back pain (LBP). The studies were largely structured as Randomized Controlled Trials (RCTs), where researchers monitored outcomes related to physical discomfort and functional limitations over specific time intervals.

The studies report how symptoms evolved in the observed populations, with some trials describing patterns observed when compared to both placebo and other established analgesic agents. Research explored whether comparative measurements against certain other pain medications in the short term could be observed.

The main evidence base for this indication is structured for short-term use. Although some historical studies monitored patient responses over intermediate durations, regulatory evaluations indicate that the research provides limited information for long-term outcomes.

Evidence for Use in Acute, Post-Event Pain

This part reviews the research foundation for the medication's evaluation in acute nociceptive discomfort, such as pain following surgical procedures or trauma. These investigations were structured as very short-term RCTs, where researchers monitored outcomes capturing episodic or acute changes in pain intensity over short, defined time intervals. Outcomes also included the time it took for an analgesic measurement to be recorded and the subsequent requirement for other pain management treatments.

Regulatory assessments confirm the research structure is limited to very short-term use, leading reviewers to focus on short-duration data. The results apply only to the populations studied in these acute settings. Some comparative evidence is lacking or findings were mixed when assessing whether observed patterns hold true for the full 48-hour period post-event compared to certain other analgesic agents.

What is Still Uncertain About the Research

There is limited information for long-term outcomes due to the short follow-up durations featured in the most definitive RCTs. Furthermore, the evidence quality varies across studies, and some key findings were derived from settings with varying symptom burdens. The research provides context but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

Restrictions in the use of flupirtine-containing medicines (2013 EMA/CMDh restrictions on short-term use and liver monitoring)

Frequently Asked Questions (FAQ)

Common questions about Katadolon PR (FAQ)

Q: Is Katadolon PR a type of opioid or a narcotic painkiller?

Official regulatory documents classify the active substance, Flupirtine maleate, as a centrally acting, non-opioid analgesic. This means its mechanism of action is distinct from traditional opioid or narcotic painkillers.

Q: What is the main difference between Katadolon PR and regular Katadolon?

The 'PR' stands for Prolonged-Release. This formulation is specifically designed to provide a sustained and continuous delivery of the active substance over time. This controlled release allows for a convenient once-daily dosing pattern, unlike immediate-release (IR) forms of the medicine.

Q: Does Katadolon PR work for nerve pain?

The medicine’s mechanism directly acts on nerve cells in the central nervous system. While the current regulatory indication is strictly for acute pain, historically, the medicine has been explored for use in certain chronic conditions, including some types of neurogenic pain.

Q: Can Katadolon PR be taken with common over-the-counter pain relievers like ibuprofen or paracetamol?

Official product information contains a specific warning regarding co-administration with Paracetamol (Acetaminophen). Combining these medicines may increase the risk of liver damage and requires strict monitoring of liver enzyme values. There is no explicit regulatory guidance regarding concurrent use with Ibuprofen.

Q: Is it safe to drive or operate machinery while taking Katadolon PR?

Regulatory documents advise caution due to common side effects. This medicine is known to cause drowsiness, dizziness, and fatigue, which may significantly impair a person’s ability to drive safely or operate heavy machinery.

Q: Does Katadolon PR have a risk of dependence or withdrawal symptoms?

Yes, official summaries indicate that the medicine has been associated with reports of dependence. In some cases, patients who stopped using the medicine after prolonged treatment experienced withdrawal symptoms, such as anxiety and tremors.

Q: What happens if I miss a dose of Katadolon PR?

Standard guidance for once-daily prolonged-release medicines typically instructs users to take a missed dose as soon as they remember. However, the label strongly cautions against taking a double dose to make up for a forgotten dose.

Q: Is Katadolon PR the same as any other pain medicine available in the US or UK?

Regulatory reviews confirm that the active substance, Flupirtine maleate, is not approved for any clinical use in the United States or Canada. It is primarily marketed and used in certain European regions under highly restricted conditions.

Q: Does research show that Katadolon PR is effective for chronic back pain?

Regulatory bodies have reviewed the evidence and concluded that the data supporting its benefits for chronic pain are less convincing than for acute pain. Consequently, its authorized use is strictly limited to acute pain relief for a maximum of 14 days.

Q: Can I stop taking Katadolon PR suddenly?

Due to documented cases of dependence and withdrawal symptoms, regulatory summaries indicate that stopping the medication requires specific medical guidance. Patients should consult a healthcare professional before making changes to their treatment regimen.

Q: Is there a link between Katadolon PR and changes in mood or anxiety?

Yes, adverse reaction reports indicate that symptoms of anxiety and mood alterations have been reported. These changes often occur as part of a withdrawal syndrome experienced by patients upon stopping the medication.

Q: What does the term 'Centrally acting analgesic' mean for Katadolon PR?

The term indicates that the medicine works directly on the Central Nervous System (CNS), which includes the brain and spinal cord. Its primary action is to modulate or regulate the transmission of pain signals centrally, rather than targeting inflammation at an injury site.

Q: Is Katadolon PR used to treat headaches or migraines?

Historically, the active substance was used for conditions like migraines in some countries. However, due to safety concerns, its current regulatory indication is now strictly limited to the short-term relief of acute pain.

Q: Does Katadolon PR help with inflammation?

No. Official clinical summaries classify this medicine as a non-steroidal analgesic that is specifically noted to lack anti-inflammatory (antiphlogistic) properties. Its pain relief mechanism is distinct from NSAIDs.

Q: Why are there different strengths of Katadolon PR available?

Different strengths or forms are necessary to comply with regulatory requirements for dosage adjustments. For example, older adults and patients with liver or kidney impairment are mandated to receive a 50% reduced dose.

Q: Is Katadolon PR available as a generic medicine?

Yes. The active ingredient, Flupirtine maleate, is sold under many generic brand names in the markets where it is approved for use, following the expiration of the original patent.

Q: What is the current regulatory status of Katadolon PR in major markets?

In the European Union, its use is severely restricted to acute pain for a maximum of 14 days due to liver safety concerns. The medicine is not approved or available in major markets such as the US or Canada.

Q: What research is available on the safety of Katadolon PR?

Regulatory bodies have conducted extensive reviews of the safety data, particularly concerning the risk of serious hepatotoxicity (liver damage). These reviews led directly to the implementation of the current, severely restrictive rules on its duration of use.

Q: Does the time of day matter when taking Katadolon PR?

The medicine is designed for a once-daily dosing pattern. While regulatory instructions do not mandate a specific time of day, this pattern is intended to maintain consistent pain relief.

Q: Is Katadolon PR a controlled substance?

No. According to the World Health Organization's ATC classification, it is categorized as a central analgesic. It is not scheduled as a controlled substance like opioids in the major jurisdictions where it is approved for use.

Q: Can I take Katadolon PR if I'm already taking an antidepressant?

Regulatory information indicates a potential drug-drug interaction with certain antidepressant medications, such as Amitriptyline. This interaction may result in increased serum levels of one or both drugs.

Q: Is it true that Katadolon PR can cause problems with balance?

Adverse reactions listed in official documents include dizziness and confusion. These are effects on the central nervous system that may affect coordination and balance, and patients are cautioned accordingly.

Q: What is the difference between Katadolon PR and non-PR Katadolon regarding how long they stay in the body?

The prolonged-release (PR) formulation is designed to extend the duration of the drug’s presence in the body. While the non-PR form has an elimination half-life of approximately 6.5 hours, the PR design extends this duration to provide sustained relief.

Q: Will taking Katadolon PR affect the results of any medical tests?

Yes, taking this medicine can potentially cause false-positive results for certain urinary metabolites (such as urobilinogen, bilirubin, or protein) when tested using standard urine test strips.

How should Katadolon PR be stored and disposed of?

Official Storage and Disposal Instructions

The storage and disposal of Katadolon PR (flupirtine maleate prolonged-release tablets) are governed by official regulatory requirements to maintain product stability and ensure environmental protection.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C.
Protection	Must be kept in the original package to protect from light and moisture.
Prohibited Storage	Do not refrigerate or freeze the medicine.
Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Katadolon PR must not be disposed of via wastewater or regular household waste. Disposal must be carried out according to local requirements for unused medicines, typically by returning them to a pharmacy or an authorized collection point.

Katadolon PR